ETIS International

"X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies..."  hit headlines earlier in April on an international level.  Headlines however ostensibly in sector framework.  In other words, unless you were looking for news of that subject, it might have been hard to find.

Version of the article located at   and  starts out with "WALTHAM, Mass. and LIANYUNGANG, China, April 4, 2013 /PRNewswire/ -- X-BODY BIOSCIENCES announced today an exclusive alliance with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), in which Hengrui will develop and commercialize a novel antibody program generated from X-BODY's antibody platform for Age-related Macular Degeneration (AMD) in Greater China (including mainland China, Taiwan, Macao, and Hong Kong).

Under the terms of the collaboration, Hengrui will fund and lead all preclinical and clinical development, as well as commercialization efforts, for the Greater China markets."

Looking at the last two sentences together with the headline.  Taking the same idea, and flipping it around in some ways, or a kind of reciprocal.  Something along those lines, funding a research project exclusively to figure out how to bring the real estate market, and possibly other sectors, to upswing and conditions of ideal, might be an idea.

Of course there are projects of this sort already, which might include volunteers forming groups on their own volition, at the lower level of the 'official' echelons. 

The best thing to do is keep striving for the best.